Almac Diagnostics discusses new biomarker service

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmacology

Almac Diagnostics discusses new biomarker service
Almac says an effective biomarker strategy boosts a drug candidates’ chance of success and can ultimately add value to a developer’s business by opening door to diagnostics.

Earlier this month Almac’s diagnostics arm launched a new biomarker development service which, as VP of business development Michael Sloan told Outsourcing-pharma, is intended to cater for growing biopharmaceutical manufacturing sector demand.

Sloan explained that demand for pharmacodynamic biomarkers, as well as those for clinical trial enrichment, is increasing day by day as everyone from Big Pharma to biotech recognises their value in the drug development process.

He also suggested that, increasingly, such companies are adopting broader strategies involving commercial development of biomarkers for in clinic diagnostics purposes which, while a new market, is one in which he sees considerable growth potential.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers